Clinical Trials Logo

Parkinsonian Disorders clinical trials

View clinical trials related to Parkinsonian Disorders.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06350617 Recruiting - Clinical trials for Parkinson's Disease and Parkinsonism

Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD Patients

Start date: February 20, 2024
Phase: N/A
Study type: Interventional

The objective of this study was to determine the effects of protocols of repetitive transcranial magnetic stimulation (rTMS) therapy based on the functional reserve of each patient with Parkinson's disease, compared to conventional high-frequency rTMS therapy on bilateral primary motor cortex (M1). Investigators hypothesized that the functional reserve of each patient with Parkinson's disease will be different, and therefore an appropriate simulating target for rTMS therapy is needed. In addition, this approach could be more effective compared to conventional protocols applied to patient with Parkinson's disease regardless of their severity, predicted mechanism of motor function recovery, or functional reserves.

NCT ID: NCT06247423 Recruiting - Nerve Block Clinical Trials

High-frequency Alternating Current Stimulation for Tremor in Parkinson's Disease.

Start date: February 2, 2024
Phase: N/A
Study type: Interventional

The goal of this randomized, double-blind, placebo-controlled, crossover study is to test the effectiveness of 10 kilohertz (kHz) high-frequency transcutaneous stimulation for tremor in people with Parkinson's disease. The main questions it aims to answer are: - Compare the effectiveness between sham stimulation and real stimulation (10kHz) for different types of tremors [rest tremor, postural tremor, kinetic tremor], fine motor skills, and maximal isometric handgrip strength. - Register adverse events, the blinding success of participants and evaluator, and subjective perception of tremor improvement. Participants will perform the following tasks in an "off" state (without levodopa and dopamine agonists medication). All of them were performed on the upper limb with more tremor. - Rest Tremor: Forearm on the armrest, count backward from 100 to 0 as fast as possible for 1 minute and 30 seconds. - Postural Tremor: Extend the arm parallel to the floor (90º shoulder flexion with the forearm extended) for 30 seconds. - Kinetic Tremor: Hold a cup by the handle, raise it close to the mouth for 3 seconds, then return to the initial position. - Fine Motor Skills: Complete the nine-hole peg test, placing pegs into holes as quickly as possible. - Handgrip Strength: Squeeze the device as strongly as possible for 3 seconds, then rest for 15 seconds.

NCT ID: NCT06203106 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

NYSCF Scientific Discovery Biobank

Start date: November 10, 2022
Phase:
Study type: Observational

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.

NCT ID: NCT06193278 Recruiting - Clinical trials for Transcranial Direct Current Stimulation

Individual Neuromodulation for PDS

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

Parkinsonian Syndromes (PDS) with predominant motor dysfunction include progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal degeneration (CBD). Current treatment options for PDS are extremely limited due to the less understanding of disease pathophysiology and lack of therapeutic targets. Combining the results of previous studies and our group's previous research, sixty qualified PDS patients would be enrolled to conduct a prospective single-center randomized sham controlled clinical trial to verify the new therapeutic options that can improve symptoms and effectively slow the progression of the disease.

NCT ID: NCT06193252 Recruiting - Parkinson Disease Clinical Trials

Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

Slow-SPEED-NL
Start date: January 15, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to investigate the feasibility if a remotely administered smartphone app can increase the volume and intensity of physical activity in daily life in patients with isolated Rapid Eye Movement (REM) sleep behaviour disorder over a long period of time (24 months). Participants will be tasked to achieve an incremental increase of daily steps (volume) and amount of minutes exercised at a certain heart rate (intensity) with respect to their own baseline level. Motivation with regards to physical activity will entirely be communicated through the study specific Slow Speed smartphone app. Primary outcomes will be compliance expressed as longitudinal change in digital measures of physical activity (step count) measured using a Fitbit smartwatch. Exploratory outcomes entail retention rate, completeness of remote digital biomarker assessments, digital prodromal motor and non-motor features of PD, blood biomarkers and brain imaging markers. Using these biomarkers, we aim to develop a composite score (prodromal load score) to estimate the total prodromal load. An international exercise study with fellow researchers in the United States and United Kingdom are currently in preparation (Slow-SPEED). Our intention is to analyse overlapping outcomes combined where possible through a meta-analysis plan, to obtain insight on (determinants of) heterogeneity in compliance and possible efficacy across subgroups

NCT ID: NCT06161636 Recruiting - Healthy Clinical Trials

Contribution of the Kinematic Theory in the Early Differential Diagnosis of the Parkinson's Disease

Start date: June 15, 2023
Phase:
Study type: Observational

The working hypotheses are as follows: #1 The processing of performance signals by automated lognormal segmentation and the extraction of the parameters of interest will make it possible to distinguish groups of patients from healthy elderly subjects. #2 The three instrumental approaches will not have the same degree of reliability as a predictive biomarker of clinical diagnosis established by consensus.

NCT ID: NCT06122662 Recruiting - Clinical trials for Neurodegenerative Diseases

AMX0035 and Progressive Supranuclear Palsy

ORION
Start date: December 21, 2023
Phase: Phase 3
Study type: Interventional

ORION Trial is a trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of a randomized double blind placebo controlled phase, followed by an optional open-label extension phase.

NCT ID: NCT06036771 Recruiting - Clinical trials for Parkinson's Disease and Parkinsonism

Voice-activated Intelligent Personal Assistant (VIPA) Intervention for People With Parkinson's Disease

Start date: August 6, 2023
Phase: N/A
Study type: Interventional

This pilot randomized control trial (RCT) aims to develop a Voice-activated Intelligent Personal Assistance (VIPA) user protocol and study its feasibility and preliminary efficacy among 60 People with Parkinson's disease (PWP). The research questions are: Phase 1: 1. What components should be included in the VIPA user protocol community-dwelling PWP? 2. Is it feasible to implement the VIPA intervention in the PD population? 3 focus group interviews and 3 cognitive interviews will be held to formulate the VIPA user protocol. 5 healthcare and information technology experts will be invited to rate the relevancy of the formulated protocol and the item content validity index will be calculated by the researcher. Phase 2: 1. What is the preliminary efficacy of VIPA intervention on SOC and psychosocial well-being? 2. Can such effect sustain for 4 weeks? 3. What is the users' experience on the VIPA intervention? 60 participants will be randomized into the intervention group (IG) and control group (CG). During the 8-week intervention period, IG participants will receive the following materials: 1. User protocol 2. Designate VIPA 3. 30-minute VIPA training on day 1 4. Weekly technical support phone calls. CG participants will receive usual care, no intervention will be provided to CG participants, and they will continue their daily life during the intervention period. The researcher will compare both groups to study the feasibility and preliminary efficacy of the VIPA on the participants' psychosocial well-being and sense of coherence.

NCT ID: NCT06032585 Recruiting - Dementia Clinical Trials

TRANSPARK_LONG: The Diagnostic Value of Early Transcranial Ultrasound in Patients With Extrapyramidal Diseases in a Swedish Population

Start date: February 8, 2024
Phase:
Study type: Observational

Popular science summary of the project The purpose of the study is to investigate in a Swedish population how well the investigators' previous ultrasound findings match the final diagnosis (PD, APS or ET) after a particularly long follow-up time, which greatly increases the certainty that the diagnosis does not change more and is thus correct. Furthermore, the investigators want to study whether the initial ultrasound findings have changed during the control interval and whether measurement results regarding the diameter in one of the fluid-filled rooms in the brain (third ventricle) can be correlated with the development of cognitive impairment or dementia later in the course of the disease. For this, this study have got ethical permission to go into the patients' medical records and to call a subgroup back to the clinic to be able to do a new examination and a memory test.

NCT ID: NCT06010290 Recruiting - Parkinson Disease Clinical Trials

The Novel 18F-labeled MAO-B PET Tracer Study in Parkinsonism Patients

Start date: November 30, 2022
Phase:
Study type: Observational

This study mainly aims to prospectively evaluate the changes of reactive astrogliosis in Parkinsonism patients of Chinese population by the novel 18F-labeled MAO-B PET tracer.